2026
conference-abstract
OpenAlex
Giovanni Lughezzani, Benedetto Calabrese, Giuseppe Chiarelli, Alessio Finocchiaro et autres
321 Background: Family history represents a significant risk factor for prostate cancer (PCa), emphasizing its genetic basis. Early identification of germline pathogenic variants (PVs) in DNA repair genes (DRGs) is crucial for timely PCa diagnosis, prognosis, and for informing at-risk relatives. Conversely, …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Vittorio Fasulo, Benedetto Calabrese, Giovanni Lughezzani, Pier Paolo Avolio et autres
323 Background: A positive family history is a well-established risk factor for prostate cancer (PCa), making the identification of individuals with inherited susceptibility particularly relevant. The detection of germline pathogenic variants (PVs) in DNA-repair genes (DRGs) further supports the implementation of targeted …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Giovanni Lughezzani, Rodolfo Hurle, Paolo Casale, Alberto Rosario Saita et autres
868 Background: The aim of this study is to evaluate the awareness of Bladder Cancer (BC) in families with at least one affected Caucasian ancestry member harbouring germline variants in DNA‐repair genes (gDRGs). Methods: Data were collected from a prospective, monocentric cohort …
it
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Marco Paciotti, Francesco Sormani, Andrea Piccolini, Mario Tiscione et autres
727 Background: While transurethral resection of bladder tumor (TURBT) remains the gold-standard treatment for non–muscle-invasive bladder cancer (NMIBC), there is growing interest in de-intensification strategies aimed at reducing the patient burden of repeated procedures and the overall economic impact of the disease. …
it
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Rodolfo Hurle, Massimo Lazzeri, Alberto Rosario Saita, NicolòMaria Buffi et autres
808 Background: The introduction of the “BCG-unresponsive” definition by the U.S. Food and Drug Administration (FDA) has provided a structured framework for classifying patients unlikely to benefit from BCG therapy, accelerating the approval of novel therapeutic agents. There is an urgent need …
it
(code pays fourni par la source)